man.1-7 Low expression is found in brain and liver.
SOD3 is a tretrameric glycoprotein with a molecular
weight ~30 kDa. The enzyme contains an 18 amino
acid signal peptide preceding the 222 amino acids
Transduction P
y y n/d
197 Cdc7 Kinase C6613 Signal Transduction M y n/d n/d
198 PAK phospho (pS
212) Clone:PK-18 P3237 Signal Transduction M y y y
199 Phospholipase A2 group V P5242 Signal
TEST. 211–212 (2015).
6. Associates of CAPE COD Incorporated. The New FDA Guidance for Industry “Pyrogen and Endotoxins Testing: Questions and Answers”. LAL
Updat. 20, 1–4 (2002).
7. Wunderlich
Calculation was performed for each product solu-
tion and each incubation condition (20 –25 °C on
212 PDA Journal of Pharmaceutical Science and Technology
on June 29, 2017journal.pda.orgDownloaded
+Cy5 C0992 NA NA M
169 Ciliated Cell Marker C5867 NA NA M y n/d n/d
192 Anti Cy3+Cy5 C0992 NA NA M
212 Pan Cytokeratin C2931 NA NA M y y y
216 Anti Cy3+Cy5 C0992 NA NA M
225 Dnase I D0188 NA
+Cy5 C0992 NA NA M
169 Ciliated Cell Marker C5867 NA NA M y n/d n/d
192 Anti Cy3+Cy5 C0992 NA NA M
212 Pan Cytokeratin C2931 NA NA M y y y
216 Anti Cy3+Cy5 C0992 NA NA M
225 Dnase I D0188 NA
+Cy5 C0992 NA NA M
169 Ciliated Cell Marker C5867 NA NA M y n/d n/d
192 Anti Cy3+Cy5 C0992 NA NA M
212 Pan Cytokeratin C2931 NA NA M y y y
216 Anti Cy3+Cy5 C0992 NA NA M
225 Dnase I D0188 NA
IgG 250 µg 06-497 $319
Anti-PI 3-Kinase, p85, N-SH3, clone AB6 H M WB IP IC M IgG1κ 100 µg 05-212 $339
Anti-PI 3-Kinase, p85, N-SH2, clone UB93-3 H M R WB IP M IgG 200
y n/d y
210 Cytokeratin peptide 18 C1399 M y n/d n/d
211 Cytokeratin peptide 19 C6930 M y n/d n/d
212 Pan Cytokeratin P2871 M y y y
213 DAPK D2178 M y n/d
behaviors such as these may soon become widespread in
tissue engineering and tissue model engineering.210–212
Physical Properties
Several physical properties must be considered for the clinical
translation
behaviors such as these may soon become widespread in
tissue engineering and tissue model engineering.210–212
Physical Properties
Several physical properties must be considered for the clinical
translation
KRT18 NP_954657.1 M y n/d n/d
211 Cytokeratin peptide 19 C6930 3880 KRT19 NP_002267.2 M y n/d n/d
212 Pan Cytokeratin P2871 M y y y
213 DAPK D2178 1611 DAP NP_004385.1 M y
KRT18 NP_954657.1 M y n/d n/d
211 Cytokeratin peptide 19 C6930 3880 KRT19 NP_002267.2 M y n/d n/d
212 Pan Cytokeratin P2871 M y y y
213 DAPK D2178 1611 DAP NP_004385.1 M y